Improved Profitability and Operating Performance
Adjusted EBITDA loss improved to -$3.1M in Q1 2026 from -$12.2M in Q1 2025 (a $9.1M improvement). Operating loss improved ~43% year-over-year to -$17.4M from -$30.4M.
Large Reduction in 2025 Losses
Company reduced net loss and adjusted EBITDA losses by approximately $100M in 2025, reflecting significant cost and operating improvements.
Stronger Visit Mix and Higher-Value Care
Amwell Medical Group (AMG) visit revenue was $28.9M, up ~9% year-over-year. AMG paid visits ~382k (slightly up YoY) and revenue per visit rose to ~$76, up ~$5 per visit YoY. Virtual primary care visits increased ~57% YoY.
Subscription Mix and Renewals Momentum
Subscription revenue represented ~53% of total revenue (a larger recurring mix). Renewals and retention in Q1 were higher than budgeted; Elevance Health renewed for three years, a meaningful validation.
Strong Cash Position and Lower Cash Burn
Ended the quarter with $179M in cash and investments (CEO cited $182M earlier), zero debt. Q1 cash burn ~ $3.1M, down from $19M in the prior quarter, underpinning confidence in reaching cash flow breakeven in Q4 2026.
Significant Pipeline Growth and Government Validation
Management reported pipeline is a multiple of last year (CFO indicated closer to triple-digit growth). DHA (Defense Health Agency) deployment and military health system contract extension provide government-scale validation; DHA renewal expected around end of Q2/start of Q3.
Tighter Cost Structure
Total operating expenses decreased ~31% YoY and operating expenses as a percentage of revenue improved to 82.6% from 98.3% in Q1 2025, supporting margin and profitability trajectory.